What can the clinician expect today from PSA determination? (Q73696103)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

reason for deprecated rank

title

Que peut attendre aujourd'hui le clinicien du dosage du PSA ? (French)

marking inconsistent with the registered/official identifier/name

1 reference

Crossref

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

reason for deprecated rank

16 November 2024

What can the clinician expect today from PSA determination? (English)

marking inconsistent with the registered/official identifier/name

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9296766

16 November 2024

P. Teillac

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9296766

16 November 2024

language of work or name

French

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9296766

16 November 2024

publication date

1 April 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

April 1994

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9296766

full work available at URL

16 November 2024

https://api.elsevier.com/content/article/PII:0969805194900698?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

https://api.elsevier.com/content/article/PII:0969805194900698?httpAccept=text/plain

16 November 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Nuclear Medicine and Biology

16 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

455-469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prevalence and Pathological Extent of Prostate Cancer in Men with Prostate Specific Antigen Levels of 2.9 to 4.0 NG./ML

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific Antigen

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Is Prostate Specific Antigen of Clinical Importance in Evaluating Outcome after Radical Prostatectomy

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Routine screening for cancer of the prostate

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Diagnostic Methods in the Detection of Prostate Cancer: A Study of a Randomly Selected Population of 2,400 Men

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

An Analysis of Urinary Prostate Specific Antigen Before and After Radical Prostatectomy: Evidence for Secretion of Prostate Specific Antigen by the Periurethral Glands

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: Followup

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

The value of serum prostate specific antigen determinations before and after radical prostatectomy

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Reevaluation of prostate biopsy after definitive radiation therapy

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Large, Organ Confined, Impalpable Transition Zone Prostate Cancer: Association with Metastatic Levels of Prostate Specific Antigen

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Early Detection of Residual Prostate Cancer After Radical Prostatectomy by an Ultrasensitive Assay for Prostate Specific Antigen

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Clinical stage Bo or T1c prostate cancer: Nonpalpable disease identified by elevated serum prostate-specific antigen concentration

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Recurrent Prostate Cancer Despite Undetectable Prostate Specific Antigen

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP

16 November 2024

1 reference

https://api.crossref.org/works/10.1016/0969-8051(94)90069-8

16 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9296766%20AND%20SRC:MED&resulttype=core&format=json